[go: up one dir, main page]

WO2013055302A9 - Effervescent composition comprising n-acetylcysteine and doxophylline or theophylline - Google Patents

Effervescent composition comprising n-acetylcysteine and doxophylline or theophylline Download PDF

Info

Publication number
WO2013055302A9
WO2013055302A9 PCT/TR2012/000082 TR2012000082W WO2013055302A9 WO 2013055302 A9 WO2013055302 A9 WO 2013055302A9 TR 2012000082 W TR2012000082 W TR 2012000082W WO 2013055302 A9 WO2013055302 A9 WO 2013055302A9
Authority
WO
WIPO (PCT)
Prior art keywords
acetylcysteine
doxophylline
theophylline
effervescent composition
combining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2012/000082
Other languages
French (fr)
Other versions
WO2013055302A1 (en
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2013055302A1 publication Critical patent/WO2013055302A1/en
Publication of WO2013055302A9 publication Critical patent/WO2013055302A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical formulations prepared by combining a mucolytic agent N-Acetylcysteine with a xanthine derivative compound, their preparation method and use in treatment of respiratory tract diseases.
PCT/TR2012/000082 2011-05-16 2012-05-14 Effervescent composition comprising n- acetylcysteine and doxophylline or theophylline Ceased WO2013055302A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2011/04738 2011-05-16
TR2011/04738A TR201104738A2 (en) 2011-05-16 2011-05-16 Pharmaceutical combination containing N-Acetylcysteine.

Publications (2)

Publication Number Publication Date
WO2013055302A1 WO2013055302A1 (en) 2013-04-18
WO2013055302A9 true WO2013055302A9 (en) 2013-08-01

Family

ID=47430028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2012/000082 Ceased WO2013055302A1 (en) 2011-05-16 2012-05-14 Effervescent composition comprising n- acetylcysteine and doxophylline or theophylline

Country Status (2)

Country Link
TR (1) TR201104738A2 (en)
WO (1) WO2013055302A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3184505A (en) 1962-06-18 1965-05-18 Mead Johnson & Co Process for the n-monoacylation of cysteine
IT1113122B (en) 1978-04-06 1986-01-20 Abc Ist Biolog Chem Spa PHARMACEUTICAL COMPOSITION WITH ANTIBROCOSPASTIC AND ANTITOSSE ACTIVITIES
DE2842822C3 (en) * 1978-09-30 1982-05-19 Merz + Co GmbH & Co, 6000 Frankfurt Medicinal preparations of poorly soluble medicinal substances in the form of effervescent granules
CH667590A5 (en) * 1986-07-24 1988-10-31 Inpharzam Int Sa WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. .
EP2130443A1 (en) * 2008-06-06 2009-12-09 Finzelberg GmbH & Co. KG Water-soluble extracts of Artemisia dracunculus (tarragon) for improvement of glucose metabolism
EP2571499A1 (en) * 2010-05-18 2013-03-27 Mahmut Bilgic Pharmaceutical composition comprising n- acetylcysteine and a xanthine

Also Published As

Publication number Publication date
WO2013055302A1 (en) 2013-04-18
TR201104738A2 (en) 2012-12-21

Similar Documents

Publication Publication Date Title
WO2012021715A3 (en) Stable formulations of linaclotide
IL232267A (en) (4-phenylimidazol-2 -yl) ethylamine derivatives, pharmaceutical compositions containing same and uses thereof in the treatment of diseases for which inhibition of the nav1.8 sodium channel is indicated
MX351584B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration.
WO2012135619A3 (en) Intranasal benzodiazepine pharmaceutical compositions
WO2012154885A3 (en) Carbonic anhydrase targeting agents and methods of using same
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2012047951A3 (en) Human lung stem cells and uses thereof
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2013117744A3 (en) Methods of treating fibrosis
HK1208222A1 (en) Modified release formulations for oprozomib
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
TN2016000121A1 (en) Cyclic thienouracil-carboxamides and use thereof
WO2012019428A8 (en) Benzohydrol derivatives, a preparation process and pharmaceutical use thereof
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
CL2013003556A1 (en) Phthalazinone-pyrrolo [3,2-d] pyrimidine-carboxamide derivatives, phosphodiesterase type 4 and type 5 inhibitors; pharmaceutical composition that comprises or fixed combination, not fixed and kit, use of the compound in the preparation of a medicament for treating respiratory tract diseases
WO2014027979A3 (en) Tablet formulations comprising tadalafil and dapoxetine
EA201270411A1 (en) SYNTHETIC HYBRID HYDROTALCITE-EUDRAGID URSODEOXYCHOLEIC ACID CONTAINING ITS PHARMACEUTICAL COMPOSITION AND METHOD FOR THEIR PRODUCTION
WO2013055302A9 (en) Effervescent composition comprising n-acetylcysteine and doxophylline or theophylline
WO2013054364A3 (en) Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
PH12016501553A1 (en) Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12806190

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12806190

Country of ref document: EP

Kind code of ref document: A1